Is My Molecule Suitable For An Orally Disintegrating Tablet?

By Susan Banbury, PhD, Head of Formulation, Product Development; Adina Dîrlea; Senior Formulation Scientist, Formulation Development; Charli Smardon, Formulation Scientist, New Product Development, Catalent; and Simon A. Lawton, MD, VP of Global Medical Affairs, ALK

Innovations in drug delivery formats are transforming the pharmaceutical industry by enabling more patient-centric treatments and helping to boost patient compliance and therapeutic efficacy. Orally Disintegrating Tablets (ODTs) are a patient-preferred dose form that offers additional potential benefits related to pregastric API delivery and absorption.

While new drug products may benefit from ODT formulation beginning with product launch, ODT formulation can also play a role in life cycle management of approved products. API suitability for an ODT is dependent on multiple factors, including delivery target and physicochemical profile. Learn about the new advances being developed to expand the potential of this technology.